Silence Therapeutics plc (SLN, SLNCF) (CIK 0001479615) (SLN)
Activity window: Oct. 25, 2025 to Oct. 24, 2026
Export this company’s current score, component values, matched signals, and scoring date as a one-row CSV snapshot.
The total combines correspondence volume, AI sentiment, matched keywords and signals, and a weighted 8-K adjustment, capped at 10.0. This is the 365-day v1 snapshot. Computed: Oct. 24, 2026. Latest filing activity: May. 22, 2026. These dates describe different events.
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| May. 22, 2026 | CORRESP | Neutral/Informational | Moderate | Silence Therapeutics plc has submitted a request to the U.S. Securities and Exchange Commission (SEC) for the acceleration of the effectiveness of their Registration Statement on … | Read Filing EDGAR |
| May. 22, 2026 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Silence Therapeutics plc that it will not review their registration statement filed on May 18, 2026. The letter emphasizes that the responsibility for … | Read Filing EDGAR |
| Jan. 9, 2026 | UPLOAD | Neutral/Informational | Low | The SEC has completed its review of Silence Therapeutics plc's Form 10-K for the fiscal year ended December 31, 2024. They remind the company that it is ultimately responsible for… | Read Filing EDGAR |
| Dec. 31, 2025 | CORRESP | Neutral/Informational | Moderate | Silence Therapeutics plc has responded to a request from the SEC for additional disclosure regarding their research and development expenses. The SEC requested a breakdown of thes… | Read Filing EDGAR |
| Dec. 18, 2025 | UPLOAD | Concern from SEC | High | The SEC has conducted a limited review of Silence Therapeutics plc's Form 10-K for the fiscal year ended December 31, 2024, focusing specifically on the financial statements and r… | Read Filing EDGAR |